secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K/A
Filed at:   2026-06-18T20:06:18+00:00
Accession:  0001193125-26-275815
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

enGene cuts workforce 50%, grants CEO performance options tied to detalimogene BLA and FDA approval milestones
--------------------------------------------------------------------------------

- Workforce reduction of ~50% approved June 14; estimated cash restructuring costs $5.7-6.4M, non-cash stock comp $4.7-5.0M.
- Performance-based equity retention awards (options and RSUs) approved June 16, vesting upon FDA acceptance of detalimogene BLA (by Sep 30, 2027) and FDA approval (by Dec 31, 2028).
- CEO Ronald Cooper granted 400,000 performance-based options at $1.75/share, vesting 50% per milestone.
- Retention costs: up to $1.7M cash and $2.8M non-cash stock comp.
- Majority of expenses expected in H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/0001193125-26-275815-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526275815/engn-20260616.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-275815

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer